BB Biotech AG reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported revenue was CHF 0.06 million compared to CHF 144.26 million a year ago. Net loss was CHF 233.07 million compared to net income of CHF 128.55 million a year ago. Basic loss per share from continuing operations was CHF 4.23 compared to basic earnings per share from continuing operations of CHF 2.32 a year ago. Diluted loss per share from continuing operations was CHF 4.23 compared to diluted earnings per share from continuing operations of CHF 2.32 a year ago.
For the six months, revenue was CHF 0.783 million compared to CHF 379.82 million a year ago. Net loss was CHF 532.93 million compared to net income of CHF 349.5 million a year ago. Basic loss per share from continuing operations was CHF 9.66 compared to basic earnings per share from continuing operations of CHF 6.31 a year ago. Diluted loss per share from continuing operations was CHF 9.66 compared to diluted earnings per share from continuing operations of CHF 6.31 a year ago.